Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...
A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...
Patients share their unexpected journeys with multiple myeloma, revealing challenges and resilience in the face of a cancer diagnosis. Patients share their emotional journeys and coping strategies ...
In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...
-- Company to host a live webcast event with an expert panel of clinicians during ASH -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell ...
Berenson Cancer Center published survival data analyzed by the Institute for Myeloma & Bone Cancer Research of 175 consecutive and unselected patients with multiple myeloma in the journal ...
A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell ...
Phase 3 AQUILA study showed DARZALEX FASPRO ® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Landmark approval supports ...
Following a strong early showing of Tecvayli and Darzalex Faspro in newly diagnosed multiple myeloma patients last month, Johnson & Johnson is making the case for its oncology cocktail as a potential ...
PET/CT scans are crucial for staging, treatment response monitoring, and detecting extramedullary disease in multiple myeloma patients undergoing CAR T-cell therapy. Bone-independent extramedullary ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results